GlassScriptPhysician profile
John Michael Strayhorn
NPI 1194725820
$1,266.73
in general payments reported to CMS, 2019-2025
25 companies · $21.78 in 2025
The $21.78 reported for 2025 was less than what a typical Cardiovascular Disease provider received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $138 · 2020: $78.82 · 2021: $306 · 2022: $308 · 2023: $225 · 2024: $190 · 2025: $21.78.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $436.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $435.79 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $243.73 | 2019-2024 | Otezla, Repatha |
| Novartis Pharmaceuticals Corporation | $153.31 | 2023-2024 | |
| W. L. Gore & Associates, INC. | $123.22 | 2022 | |
| Abbott Laboratories | $121.97 | 2022-2025 | Freestyle Libre 3 |
| Abbvie INC. | $98.22 | 2021-2024 | |
| E.R. Squibb & Sons, L.L.C. | $73.11 | 2019-2024 | Eliquis, Camzyos |
| Allergan, INC. | $50.10 | 2019-2020 | |
| Glaxosmithkline, LLC. | $32.66 | 2022-2023 | Shingrix |
| Merck Sharp & Dohme LLC | $29.66 | 2021-2022 | |
| Lilly USA, LLC | $29.54 | 2021-2024 | Zepbound, Jardiance |
| Eisai INC. | $28.09 | 2021 | |
| Amarin Pharma, INC. | $27.83 | 2021 | |
| Alnylam Pharmaceuticals INC. | $26.12 | 2021 | |
| Arbor Pharmaceuticals, INC. | $25.51 | 2021-2022 | |
| Sanofi Pasteur INC. | $24.94 | 2019-2020 |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $22.65 | 2021 | |
| Boston Scientific Corporation | $21.03 | 2024 | Watchman Flx |
| Almatica Pharma LLC | $20.78 | 2021 | |
| Evoke Pharma, INC. | $20.05 | 2022 | |
| Avanos Medical | $19.26 | 2021 | |
| Nestle Healthcare Nutrition INC. | $16.78 | 2022 | |
| Pfizer INC. | $16.14 | 2023 | |
| Novo Nordisk INC | $16.01 | 2024 | Wegovy |
| Nevro Corp. | $13.07 | 2022 | |
| Janssen Pharmaceuticals, INC | $12.95 | 2023 | Xarelto |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw John Strayhorn listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.